Boston Scientific invests €26m in R&D at Clonmel facility
The investment is supported by grant funding from Government through IDA Ireland
Medical device developer Boston Scientific Corporation is investing €26m (£22.7 m) in r&d at its Clonmel facility in Ireland.
The investment, supported by the Government through IDA (Industrial Development Agency) Ireland, will enable Boston Scientific to significantly expand its r&d and technical capabilities related to the design of the company’s next-generation cardiac rhythm management devices manufactured at the Clonmel facility.
Brad Sorenson, vice-president of Operations for Boston Scientific, said: “This local funding will benefit our Cardiology, Rhythm and Vascular Group by enhancing our ability to provide r&d, design and manufacturing support for our leading medical device technologies.”
Boston Scientific is a major player in the medical technologies sector in Ireland having established operations in there in 1994 and is one of the country’s largest employers, with campuses in Clonmel, Galway and Cork.
